These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26009618)

  • 1. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
    Pasipanodya J; Gumbo T
    Antimicrob Agents Chemother; 2011 Jan; 55(1):24-34. PubMed ID: 20937778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
    Liu Y; Moodley M; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0140122. PubMed ID: 36877034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical models for antituberculosis drug development: a landscape analysis.
    Gumbo T; Lenaerts AJ; Hanna D; Romero K; Nuermberger E
    J Infect Dis; 2015 Jun; 211 Suppl 3():S83-95. PubMed ID: 26009617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.
    Mason AB; Dartois V
    Methods Mol Biol; 2021; 2314():715-731. PubMed ID: 34235677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
    Srivastava S; Gumbo T
    Curr Pharm Des; 2011; 17(27):2881-8. PubMed ID: 21834761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
    Budha NR; Lee RE; Meibohm B
    Curr Med Chem; 2008; 15(8):809-25. PubMed ID: 18393850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of the activity of antituberculosis drugs and regimens.
    Chirehwa MT; Velásquez GE; Gumbo T; McIlleron H
    Expert Rev Anti Infect Ther; 2019 Jun; 17(6):449-457. PubMed ID: 31144539
    [No Abstract]   [Full Text] [Related]  

  • 13. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
    Davies GR; Nuermberger EL
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S65-74. PubMed ID: 18762154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
    Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using animal models to develop new treatments for tuberculosis.
    Nuermberger E
    Semin Respir Crit Care Med; 2008 Oct; 29(5):542-51. PubMed ID: 18810687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacodynamics and pharmacokinetics of domestic fixed-dose combination of antituberculosis drugs].
    Zhao W; Li H; Duan L; Liang G; Zhang T; Lu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):333-6. PubMed ID: 12126555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.